Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
On November 8, 2024 Autolus, Inc. (“Autolus”) announced that the FDA has approved AUCATZYL (obecabtagene autoleucel) for the treatment of ...
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
Hosted on MSN11d
New CAR T-Cell Therapy Approved for LeukemiaThe FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...
1don MSN
Lawyers for Sean ‘Diddy’ Combs say prosecutors have engaged in “outrageous government conduct” by using materials seized from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback